Recommended Treatment for H. pylori Infection
For treatment-naive patients with H. pylori infection, use bismuth quadruple therapy (PPI + bismuth + tetracycline + metronidazole) for 14 days as first-line treatment when antibiotic susceptibility is unknown. 1
First-Line Treatment Options
The 2024 ACG guidelines prioritize bismuth quadruple therapy (BQT) as the preferred empiric regimen because it maintains high efficacy (>90%) even in the presence of antibiotic resistance, which now exceeds 30% for clarithromycin, levofloxacin, and metronidazole in North America 1. This represents a critical shift from older triple therapy approaches that have declined to 70-85% efficacy due to rising clarithromycin resistance 2.
Bismuth Quadruple Therapy Regimen:
- PPI (esomeprazole or rabeprazole 40 mg preferred) twice daily, 30 minutes before meals
- Bismuth subsalicylate (e.g., Pepto-Bismol) 2 tablets four times daily, 30 minutes before meals
- Tetracycline 500 mg four times daily, 30 minutes after meals
- Metronidazole 500 mg four times daily, 30 minutes after meals
- Duration: 14 days 3
Key advantage: BQT avoids the problem of antibiotic overuse and achieves acceptable success even with metronidazole-resistant strains 2. The three-in-one capsule formulation (Pylera®) simplifies administration and enhances adherence, though 10-day packaging may be insufficient—14 days is superior 4.
Alternative First-Line Options:
Rifabutin triple therapy (14 days) is suitable for patients without penicillin allergy 1:
- Rifabutin 150 mg twice daily
- Amoxicillin 1 g three times daily
- High-dose PPI (esomeprazole or rabeprazole 40 mg) twice daily
Concomitant non-bismuth quadruple therapy (14 days) is appropriate in areas of high clarithromycin resistance where bismuth is unavailable 2:
- PPI twice daily
- Amoxicillin 1000 mg twice daily
- Metronidazole 500 mg twice daily
- Clarithromycin 500 mg twice daily
Critical Treatment Principles
Duration matters: All three major consensus groups (Toronto, Maastricht V/Florence, ACG) agree that 14-day therapy achieves higher success rates than shorter durations for first-line treatment 2. The goal is to succeed on the first attempt to avoid retreatment, retesting, cost, patient anxiety, and negative impacts on gut microbiota 2.
PPI selection is crucial: Use high-potency PPIs—esomeprazole or rabeprazole 40 mg twice daily are preferred over pantoprazole, which has significantly lower potency 3. Adequate acid suppression maximizes therapeutic success, particularly with amoxicillin-containing regimens 4.
Regimens to Avoid
Do NOT use clarithromycin triple therapy empirically unless local resistance is <15% and proven to cure >90% locally 2, 3. This once-standard regimen now fails in most geographic areas due to widespread clarithromycin resistance.
Levofloxacin triple therapy is NOT first-line for most patients 2. All guidelines agree it should be reserved for rescue therapy or used only with confirmed susceptibility due to rising fluoroquinolone resistance and FDA warnings about serious side effects 3.
Sequential, hybrid, and reverse hybrid therapies are obsolete 3. These regimens include antibiotics that offer no therapeutic benefit and only increase global antimicrobial resistance.
Rescue Therapy for Treatment Failure
For patients with persistent infection after first-line therapy, "optimized" bismuth quadruple therapy for 14 days is preferred if not previously used 1. If BQT was the initial regimen, use rifabutin triple therapy for 14 days 1.
Alternative rescue options include:
- Tetracycline-levofloxacin quadruple therapy (PPI + bismuth + tetracycline + levofloxacin) achieves 98% eradication versus 69% for levofloxacin-amoxicillin triple therapy 5
- High-dose PPI-amoxicillin dual therapy (89% eradication rate) 5
Critical caveat: Salvage regimens containing clarithromycin or levofloxacin should ONLY be used if antibiotic susceptibility is confirmed 1.
Special Considerations
Penicillin allergy: BQT is the treatment of choice since it contains no beta-lactams 4.
Tetracycline unavailable: Minocycline may serve as an alternative; doxycycline is NOT recommended due to significantly lower efficacy 4.
Post-treatment confirmation: Test-of-cure is mandatory for all patients, particularly those with peptic ulcer disease, persistent symptoms, MALT lymphoma, or after gastric cancer resection 6.
Common Pitfalls
- Using 7-10 day regimens instead of 14 days for first-line therapy—this compromises eradication rates
- Prescribing clarithromycin triple therapy empirically—resistance now exceeds 30% in North America
- Using low-potency PPIs or inadequate dosing—pantoprazole should be avoided
- Failing to confirm eradication—persistent infection leads to complications
- Repeating failed antibiotic classes without susceptibility testing—this perpetuates treatment failure
The shift toward treating H. pylori as an infectious disease requiring near-100% cure rates, rather than a gastroenterological condition accepting modest success, represents the future of management 3. Success depends on choosing highly effective first-line therapy and confirming eradication in all patients.